In looking at RCE previous posts, and considering the Pasteur act has the potential to assist with security of future funding, Tuberculosis is yet another bacteria that is a likely candidate.
But like sepsis, it has a high cost to treat, possibly more than sepsis, maybe simpler to administer and potentially a smaller market for the risk/reward for RCE.
that is if the inhalant is successful.
I like the multiple fronts RCE has, is Pursuing and with IP on manufacturing, surely would limit potential competition for at the very least 10 years.
PASTEUR Act, page-17
Add RCE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
55.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $112.1M | |||
| Open | High | Low | Value | Volume |
| 55.0¢ | 55.0¢ | 54.0¢ | $23.11K | 42.17K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3018 | 54.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 55.0¢ | 2886 | 1 |
View Market Depth
| Last trade - 15.57pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
55.0¢ |
Change
0.000 ( 0.92 %) |
||||
| Open | High | Low | Volume | ||
| 54.0¢ | 55.0¢ | 54.0¢ | 22451 | ||
| Last updated 15.06pm 14/06/2024 ? | |||||
| RCE (ASX) Chart |